REG - e-Therapeutics plc - Director/PDMR Shareholding

E-TherapeuticsAnnouncement

20/02/2023 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230220:nRST4472Qa&default-theme=true

RNS Number : 4472Q  e-Therapeutics plc  20 February 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

 

Director/PDMR Shareholding

 

 

London, UK, 20 February 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a
company integrating computational power and biological data to discover
life-transforming RNAi medicines, announces that Mr Ali Mortazavi, the
Company's Chief Executive Officer, has notified the Company of the transfer of
50,941,666 Ordinary Shares for nil consideration from TS Capital/JIM Nominees
Limited to WH Ireland/SEI Investments (Europe).

 

Mr Mortazavi's shareholding is unchanged at 50,941,666 Ordinary Shares,
representing 8.75% of the Company's total issued share capital.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further details:

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Ali Mortazavi

 2    Reason for the notification    Transfer to new Nominee

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         e-therapeutics plc

 b)   LEI                                                          21380049RHSSJXWKYT18

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence each

      Identification code                                          ISIN: GB00B2823H99

 b)   Nature of the transaction                                    Transfer of shares between broker accounts. No change in beneficial ownership.

 c)   Price(s) and volume(s)

                                                                                         Price                 Volume
                                                                                         Nil                   50,941,666

 d)   Aggregated information                                       N/A - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      20 February 2023

 f)   Place of the transaction                                     Outside a trading venue

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi,                                                                        Tel: +44 (0)20 4551 8888
 CEO

                                                                                     www.etherapeutics.co.uk
 James Chandler, VP IR & Communications

      SP Angel Corporate Finance LLP                                                   Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc www.etherapeutics.co.uk
(http://www.etherapeutics.co.uk)

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets, and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary Computational Biology Platform enables the generation and
analysis of biological network models, providing a novel and mechanistic
approach to drug discovery that explicitly considers the true complexity of
biology and makes more reliable predictions from large complex data sets and
ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive
and integrated hepatocyte-centric data and information resource.  The Company
generates, prioritises and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.

 

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes
in the liver and the specific silencing of novel disease-associated genes,
identified by ETX's Computational Biology Platform.  The focus on hepatocytes
offers the opportunity to work across a wide variety of diseases.  The liver
is a highly metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of action.

 

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates
in several therapeutic areas including haematology, cardiovascular disease
and non-alcoholic steatohepatitis ("NASH").  ETX has also partnered with
biopharma companies such as Novo Nordisk, Galapagos NV and iTeos
Therapeutics using its computational network biology approach across a
diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFLIFRIIFIV